

**S/N Unknown**

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant:	Edmond J. LaVoie et al.	Examiner:	Kahsay Habte
Serial No.:	Unknown	Group Art Unit:	Unknown
Filed:	Herewith	Docket:	735.038US2
Title:	HETEROCYCLIC TOPOISOMERASE POISONS		

---

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicants respectfully request that this Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicants request that a copy of the 1449 form, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication.

Pursuant to 37 C.F.R. §1.97(b), it is believed that no fee or statement is required with the Information Disclosure Statement. However, if an Office Action on the merits has been mailed, the Commissioner is hereby authorized to charge the required fees to Deposit Account No. 19-0743 in order to have this Information Disclosure Statement considered.

Pursuant to 37 C.F.R. §1.98(d), copies of the listed documents are not provided as these references were previously cited by or submitted to the U.S. Patent Office in connection with Applicants' prior U.S. application, Serial No. 09/869141, filed on June 13, 2001, which is relied upon for an earlier filing date under 35 U.S.C. §120.

INFORMATION DISCLOSURE STATEMENT

Serial No :Unknown

Filing Date: Herewith

Title: HETEROCYCLIC TOPOISOMERASE POISONS

Page 2

Dkt: 735.038US2

The Examiner is invited to contact the Applicants' Representative at the below-listed telephone number if there are any questions regarding this communication.


Respectfully submitted,

EDMOND J. LAVOIE ET AL.

By their Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.  
P.O. Box 2938  
Minneapolis, MN 55402  
(612) 359-3265

Date 10-21-03

By   
Robert J. Harris  
Reg. No. 37,346

Express Mail" mailing label number: E298566671US

Date of Deposit: October 21, 2003

This paper or fee is being deposited on the date indicated above with the United States Postal Service pursuant to 37 CFR 1.10, and is addressed to the Assistant Commissioner for Patents, Attn: MAIL STOP PATENT APPLICATION, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	Unknown
Filing Date	Even Date Herewith
First Named Inventor	LaVoie, Edmond
Group Art Unit	Unknown
Examiner Name	Habte, Kahsay

Sheet 1 of 4

Attorney Docket No: 735.038US2

## **US PATENT DOCUMENTS**

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	Filing Date If Appropriate
	US-26,065	07/19/1966	Marvel, C. S., et al.	260	47	11/28/1965
	US-2,985,661	05/23/1961	Hien, D. W., et al.	260	309	02/09/1956
	US-3,449,330	06/10/1969	Guglielmetti, L., et al.	260	240	08/16/1965
	US-3,538,097	11/03/1970	Lowe, H., et al.	260	268	03/23/1967
	US-5,106,863	04/21/1992	Hajos, Z. G., et al.	514	395	03/26/1990
	US-5,112,532	05/12/1992	Ninomiya, H., et al.	252	587	07/24/1989
	US-5,767,142	06/16/1998	La Voie, E. J., et al.	514	394	03/20/1996
	US-5,770,617	06/23/1998	LaVoie, , et al.	514	394	01/21/1997
	US-5,807,874	09/15/1998	LaVoie, E. J., et al.	514	338	05/17/1995

## **FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	T <sup>2</sup>
	RU-1530628	12/23/1989		C07 D	235/20	
	WO-96/36612	11/21/1996	LaVoie, Edmond J., et al.	C07 D	235/18	
	WO-98/31673	07/23/1998	LaVoie, Edmond J., et al.	C07 D	235/18	

## **OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		International PCT Search Report for PCT/US 98/01005, (06/22/98), 5 pgs	
		BATHINI, YADAGIRI, et al., "Convenient Routes to Substituted Benzimidazoles and Imidazolo[4,5-b]pyridines Using Nitrobenzene as Oxidant", <u>Synthetic Communications</u> , 20 (7), (1990), pp. 955-963	
		CHEN, ALLAN Y., et al., "A New Mammalian DNA Topoisomerase I Poison Hoechst 33342: Cytotoxicity and Drug Resistance in Human Cell Cultures", <u>Cancer Research</u> , 53 (6), (March 15, 1993), pp. 1332-1337	
		CHEN, ALLAN Y., et al., "DNA Minor Groove-Binding Ligands: A Different Class of Mammalian DNA Topoisomerase I Inhibitors", <u>Proc. Natl. Acad. Sci., USA</u> , 90, (Sept. 1993), pp. 8131-8135	
		CHEN, ALLAN Y., et al., "DNA Topoisomerases: Essential Enzymes and Lethal Targets", <u>Annu. Rev. Pharmacol. Toxicol.</u> , 34, (1994), pp. 191-218	
		GOLDMAN, GUSTAVO H., et al., "Differential poisoning of humand and aspergillus nidulans DNA topoisomerase I by Bi- and Terbenzimidazoles", <u>Biochemistry</u> , 36 (21), (1997), pp. 6488-6494	
		KIM, J. S., et al., "Influence of steric factors on topoisomerase I inhibition and cytotoxicity of bisbenzimidazoles related to Hoechst 33342", <u>Proceedings of the</u>	

**EXAMINER**

**DATE CONSIDERED**

Substitute Disclosure Statement Form (PTO-1449)

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

<b>Application Number</b>	Unknown
<b>Filing Date</b>	Even Date Herewith
<b>First Named Inventor</b>	LaVoie, Edmond
<b>Group Art Unit</b>	Unknown
<b>Examiner Name</b>	Habte, Kahsay

Sheet 2 of 4

Attorney Docket No: 735.038US2

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		86th Annual Meeting of the American Association for Cancer Research, 36, Abstract No. 2689, Toronto, Ontario, Canada, (March 1995), p. 451	
		KIM, J. S., et al., "Influence of steric factors on topoisomerase I inhibition and cytotoxicity of bisbenzimidazoles related to Hoechst 33342", Abstract 7 - Proceedings of the 3rd Annual Scientific Retreat of the Cancer Institute of New Jersey, Princeton Marriott Forrestal Village, (1995), p. 28	
		KIM, JUNG S., et al., "Quantitative structure-activity relationships on 5-substituted terbenzimidazoles as topoisomerase I poisons and antitumor agents", Bioorg. Med. Chem., 6 (2), (1998), pp. 163-172	
		KIM, J. S., et al., "Steric factors associated with the topoisomerase I inhibition and cytotoxicity of substituted bisbenzimidazoles", Abstract 10- Proceedings of the American Association of Pharmaceutical Scientists Eastern Regional Meeting, (1995), p. 27	
		KIM, JUNG S., et al., "Structure-activity Relationships of Benzimidazoles and Related Heterocycles as Topoisomerase I Poisons", Bioorganic & Med. Chem., 4, (1996), pp. 621-630	
		KIM, JUNG S., et al., "Substituted 2,5'-Bi-1H-benzimidazoles: Topoisomerase I Inhibition and Cytotoxicity", J. Med. Chem., 39, (1996), pp. 992-998	
		KIM, JUNG S., et al., "Terbenzimidazoles: influence of 2", 4-, and 5-substituents on cytotoxicity and relative potency as topoisomerase I poisons", J. Med. Chem., 40, (1997), pp. 2818-2824	
		LAVOIE, E. J., et al., "Structure-activity studies related to minor groove-binding ligands which inhibit mammalian DNA topoisomerase I", Abstract 1 - Proceedings of the 85th Annual Meeting of American Association for Cancer Research, San Francisco, CA, (April 1994), p. 2699	
		LOEWE, H., et al., "Basic substituted 2, 6-bisbenzimidazole derivatives, a novel series of substances with chemotherapeutic activity", Chemical Abstracts, 82 (17), Abstract No. 112032, (April 28, 1975), 1 p.	
		PILCH, DANIEL S., et al., "A terbenzimidazole that preferentially binds and conformationally alters structurally distinct DNA duplex domains: a potential mechanism for topoisomerase I poisoning", Proc. Nat'l. Acad. Sci., USA, 94, (Dec. 1997), pp. 13565-13570	
		PILCH, DANIEL S., et al., "Biophysical Characterization of a Cytotoxic, Topoisomerase I Poison", Abstract 8 - Proceedings of the 3rd Annual Scientific Retreat of the Cancer Institute of New Jersey, Princeton Marriott Forrestal Village, Princeton, NJ, (June 1, 1995), p. 3	
		PILCH, DANIEL S., et al., "Characterizing the DNA binding modes of a topoisomerase I-poisoning terbenzimidazole: evidence for both intercalative and minor groove binding properties", Drug Design and Discovery, 13, (1996), pp. 115-133	
		PORAI-KOSHITS, B. A., et al., "Imidazole derivatives. Synthesis of some	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. † Applicant's unique citation designation number (optional) ‡ Applicant is to place a check mark here if English language Translation is attached

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

<b>Application Number</b>	Unknown
<b>Filing Date</b>	Even Date Herewith
<b>First Named Inventor</b>	LaVoie, Edmond
<b>Group Art Unit</b>	Unknown
<b>Examiner Name</b>	Habte, Kahsay

Sheet 3 of 4

Attorney Docket No: 735.038US2

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		polybenzimidazoles", Zhur. Obshchei Khim, 23, As related in Chemical Abstracts, 48 (1954) Col. 4523,(1953),pp. 835-41	
		SINGH, MALVINDER P., et al., "Synthesis and Sequence-Specific DNA Binding of a Topoisomerase Inhibitory Analog of Hoechst 33258 Designed for Altered Base and Sequence Recognition", Chem. Res. Toxicol., 5, (1992),pp. 597-607	
		SUN, et al., Chemical Abstracts, 123 (15), Abstract No. 198740r,(1995),1 p.	
		SUN, QUN , et al., "Structure activity of novel topoisomerase I inhibitors related to Hoechst 33342", Abstract 6 - Proceedings of the American Association of Pharmaceutical Scientists Eastern Regional Meeting, Hyatt Regency Hotel, New Brunswick, NJ,(June 5-6, 1995),p. 25	
		SUN, QUN , et al., "Structure Activity of Topoisomerase I Poisons related to Hoechst 33342", Bioorganic & Medicinal Chemistry Letters, Vol. 4, No. 24 Vol. 4, No. 24,(1994),pp. 2871-2876	
		SUN, QUN , et al., "Structure-activity studies related to minor groove-binding ligands which inhibit mammalian DNA topoisomerase I", Cancer Institute of New Jersey's First Annual Scientific Retreat, Abstract 2, Princeton Marriott Forrestal Village, Princeton, NJ,(June 7, 1994),p. 66	
		SUN, SUN , et al., "Synthesis and Evaluation of Terbenzimidazoles as Topoisomerase I Inhibitors", J. Med. Chem, 38, (1995),pp. 3638-3644	
		SUN, QUN , et al., "Synthesis and Evaluation of Terbenzimidazoles as Topoisomerase I Inhibitors", Chemical Abstracts, 123 (15), Abstract No.198740r,(1995),p. 1241	
		SUN, Q. , et al., "Synthesis and Pharmacological Evaluation of a Series of Novel DNA Topoisomerase I Inhibitors as Antitumor Agents", Scientific Proceedings of 86th Annual Meeting of the American Association for Cancer Research, Abstract 3, Toronto, Canada,(Mar. 18-22, 1995),1 p.	
		SUN, QUN , et al., "Synthesis and pharmacological evaluation of a series of novel DNA topoisomerase I inhibitors as antitumor agents", Proceedings of the 86th Annual Meeting of the American Association for Cancer Research, Toronto, Ontario, Canada,(1995),p. 2688	
		SUN, QUN , et al., "Synthesis and pharmacological evaluation of a series of novel DNA topoisomerase I inhibitors as antitumor agents", Abstract 5 - Proceedings of the 3rd Annual Scientific Retreat of the Cancer Institute of New Jersey, Princeton Marriott Forrestal Village, Princeton, NJ,(1995),p. 27	
		SUN, QUN , et al., "Synthesis of Benzimidazo[2,1-a]isoquinolines and 5,6-Dihydrobenzimidazo[2,1-a]isoquinolines", Syn. Lett., submitted, Paper No. 7,(1995),6 p.	
		VINOGRADOV, A. E., et al., "Some properties of new DNA specific bisbenzimidazole fluorochromes without a piperazine ring", Biotechnic & Histochemistry, 38 (5), (1993),pp. 265-269	
		YADAGIRI, BATHINI , et al., "Convenient Routes to Substituted Benzimidazoles	

**EXAMINER****DATE CONSIDERED**

Substitute Disclosure Statement Form (PTO-1449)

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 606. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Applicant Number	Unknown
Filing Date	Even Date Herewith
First Named Inventor	LaVoie, Edmond
Group Art Unit	Unknown
Examiner Name	Habte, Kahsay

Sheet 4 of 4

Attorney Docket No: 735.038US2

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		and Imidazolo[4,5-b]Pyridines Using Nitrobenzene as Oxidant", <u>Synthetic Communications</u> , 20 (7), (1990),pp. 955-963	

**EXAMINER****DATE CONSIDERED**

Substitute Disclosure Statement Form (PTO-1449)

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.  
<sup>1</sup> Applicant's unique citation designation number (optional) <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached